Journal Club 2025

journal club image Spacer Image

Next HOPA Journal Club

Tuesday, January 14, 2025 at 2 p.m. Central Time

Listen to critical evaluations of hematology/oncology pharmacy publications presented by PGY2 Oncology Residents.

Click here to register for January's Journal Club!

Spacer Image

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial

Alexander Goodridge headshot

Alexander Goodridge, PharmD, PGY2 Oncology Pharmacy Resident

Ohio Health - Riverside Methodist Hospital, Columbus, OH

Article:

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): An international, multicentre, randomised, double-blind, phase 3 study

Reem Ghandour headshot

Reem Ghandour, PharmD, PGY2 Oncology Pharmacy Resident

Emory University Hospital Midtown, Atlanta, GA

Article:

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): An international, multicentre, randomised, double-blind, phase 3 study

Spacer Image

Reserve your spot for January's Journal Club!

Want to be a Journal Club Presenter?

The next call for the January-June 2025 session speakers is currently closed. Stay tuned for future opportunities.